Abstract 135P
Background
Two classical models have been proposed for the development of colorectal cancer (CRC) from colon epithelial cells, transformation of adenoma and serrated polyps to cancer. However, clinical data showed that there is still a certain amount of CRC is not derived from the above two pathways, forming the theoretical island of CRC pathogenesis. Laterally spreading tumor (LST) is an important precancerous lesion of CRC, while the molecular mechanism of it's carcinogenesis remained unclear.
Methods
We proposed a two-stage cascade mutation hypothesis for LST cancerization. Based on the mRNA data of 25711 samples from 980 healthy donors in the genotype-tissue expression, pan-cancer mRNA-sequencing and survival data.We performed a differential expression and survival analysis of ATM, ANO5, APC, and TP53 in pan-cancer and adjacent normal samples. Furthermore, we validated the noneffective role of PIK3CA signaling pathway in two cell lines, LS174T and SW1116 by constructing three SiRNA (PIK3CA-SiRNA-1, PIK3CA-SiRNA-2, PIK3CA-SiRNA-3), to confirm the vital role of TGFβ and p53 signaling pathway involving in LST cancerization.
Results
The expression profiles of ATM, ANO5, APC and TP53 in normal and pan-cancer samples were significantly downregulated in rectal adenocarcinoma, colon adenocarcinoma, and their joint samples. In contrast, TP53 showed an obviously higher level in all of above samples. ATM, ANO5, APC, and TP53 expression were correlated with the overall survival of colorectal cancer patients. ATM and ANO5, which closely related to the Golgi apparatus fragmentation in LST samples presented a significant changes. The SiRNA interference test showed that the expression level of PIK3CA was not significantly different from the control group.
Conclusions
These findings suggested that early APC mutations induced a Golgi fragmentation event, weakened the expression of wild-type TP53 transcription factor MDM2 and TP73, modulated the stability of mutant TP53, ultimately promoted the carcinogenesis process of the LST. The PI3K signaling pathway is not closely associated with LST carcinogenesis. These observations suggest the existence of a unique and novel pathway for the development of CRC from LST.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China; Gansu Medical College.
Disclosure
The authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract